Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review
Cystic fibrosis (CF) is a multisystem disease caused by variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and resulting in deficient or dysfunctional CFTR protein [1]. F508del is the most prevalent disease-causing variant in people with CF (pwCF), occurring in 80 –85 % of cases [2,3]. The prognosis has largely been determined by the pulmonary complications of the disease.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Ilaria Testa, Giuseppe Indolfi, Rossa Brugha, Henkjan J Verkade, Vito Terlizzi Tags: Review Source Type: research
More News: Cystic Fibrosis | Genetics | Liver | Liver Transplant | Respiratory Medicine | Transplants | Urology & Nephrology